Amyloidosis and POEMS syndrome

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Importance of the field: Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. Areas covered in this review: Stem-cell transplantation and novel agents have widened the chemotherapy alternatives available in these disorders and combinations of novel agents with high-dose therapy further improve treatment options. This review covers the main areas of debate in the optimal treatment amyloidosis and POEMS patients, focusing on the implications for everyday clinical practice and management strategies published in the past 36 months. What the reader will gain: Insights into treatment strategies are provided in the review. Keys to early recognition of the syndromes are reviewed. Take-home message: With early diagnosis most patients are therapy candidates. New agents and new application of stem-cell transplantation have dramatically improved outcomes for these previously uniformly poor prognosis disorders.

Original languageEnglish (US)
Pages (from-to)1501-1514
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number9
DOIs
StatePublished - Jun 2010

Fingerprint

POEMS Syndrome
Amyloidosis
Stem Cell Transplantation
Therapeutics
Art Therapy
Practice Management
Early Diagnosis
Drug Therapy
Skin

Keywords

  • Amyloidosis
  • Bortezomib
  • Castleman's disease
  • Lenalidomide
  • Monoclonal gammopathy of undetermined significance
  • Multiple myeloma
  • Osteosclerotic multiple myeloma
  • Paraneoplastic syndrome
  • POEMS syndrome
  • Stem-cell transplantation
  • Thalidomide

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Amyloidosis and POEMS syndrome. / Chee, Cheng E.; Dispenzieri, Angela; Gertz, Morie.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 9, 06.2010, p. 1501-1514.

Research output: Contribution to journalArticle

@article{ff932cd480f94f1babbe82aa414d809c,
title = "Amyloidosis and POEMS syndrome",
abstract = "Importance of the field: Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. Areas covered in this review: Stem-cell transplantation and novel agents have widened the chemotherapy alternatives available in these disorders and combinations of novel agents with high-dose therapy further improve treatment options. This review covers the main areas of debate in the optimal treatment amyloidosis and POEMS patients, focusing on the implications for everyday clinical practice and management strategies published in the past 36 months. What the reader will gain: Insights into treatment strategies are provided in the review. Keys to early recognition of the syndromes are reviewed. Take-home message: With early diagnosis most patients are therapy candidates. New agents and new application of stem-cell transplantation have dramatically improved outcomes for these previously uniformly poor prognosis disorders.",
keywords = "Amyloidosis, Bortezomib, Castleman's disease, Lenalidomide, Monoclonal gammopathy of undetermined significance, Multiple myeloma, Osteosclerotic multiple myeloma, Paraneoplastic syndrome, POEMS syndrome, Stem-cell transplantation, Thalidomide",
author = "Chee, {Cheng E.} and Angela Dispenzieri and Morie Gertz",
year = "2010",
month = "6",
doi = "10.1517/14656561003769874",
language = "English (US)",
volume = "11",
pages = "1501--1514",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Amyloidosis and POEMS syndrome

AU - Chee, Cheng E.

AU - Dispenzieri, Angela

AU - Gertz, Morie

PY - 2010/6

Y1 - 2010/6

N2 - Importance of the field: Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. Areas covered in this review: Stem-cell transplantation and novel agents have widened the chemotherapy alternatives available in these disorders and combinations of novel agents with high-dose therapy further improve treatment options. This review covers the main areas of debate in the optimal treatment amyloidosis and POEMS patients, focusing on the implications for everyday clinical practice and management strategies published in the past 36 months. What the reader will gain: Insights into treatment strategies are provided in the review. Keys to early recognition of the syndromes are reviewed. Take-home message: With early diagnosis most patients are therapy candidates. New agents and new application of stem-cell transplantation have dramatically improved outcomes for these previously uniformly poor prognosis disorders.

AB - Importance of the field: Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. Areas covered in this review: Stem-cell transplantation and novel agents have widened the chemotherapy alternatives available in these disorders and combinations of novel agents with high-dose therapy further improve treatment options. This review covers the main areas of debate in the optimal treatment amyloidosis and POEMS patients, focusing on the implications for everyday clinical practice and management strategies published in the past 36 months. What the reader will gain: Insights into treatment strategies are provided in the review. Keys to early recognition of the syndromes are reviewed. Take-home message: With early diagnosis most patients are therapy candidates. New agents and new application of stem-cell transplantation have dramatically improved outcomes for these previously uniformly poor prognosis disorders.

KW - Amyloidosis

KW - Bortezomib

KW - Castleman's disease

KW - Lenalidomide

KW - Monoclonal gammopathy of undetermined significance

KW - Multiple myeloma

KW - Osteosclerotic multiple myeloma

KW - Paraneoplastic syndrome

KW - POEMS syndrome

KW - Stem-cell transplantation

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=77952721786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952721786&partnerID=8YFLogxK

U2 - 10.1517/14656561003769874

DO - 10.1517/14656561003769874

M3 - Article

C2 - 20426710

AN - SCOPUS:77952721786

VL - 11

SP - 1501

EP - 1514

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 9

ER -